144 related articles for article (PubMed ID: 37923688)
21. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
22. Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
Callens C; Vaur D; Soubeyran I; Rouleau E; Just PA; Guillerm E; Golmard L; Goardon N; Sevenet N; Cabaret O; Harter P; Gonzalez-Martin A; Fujiwara K; Cecere SC; Colombo N; Marth C; Vergote I; Maenpaa J; Pujade-Lauraine E; Ray-Coquard I
J Natl Cancer Inst; 2021 Jul; 113(7):917-923. PubMed ID: 33372675
[TBL] [Abstract][Full Text] [Related]
23. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
[TBL] [Abstract][Full Text] [Related]
24. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
25. Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative).
Gaba F; Ash K; Blyuss O; Bizzarri N; Kamfwa P; Ramirez PT; Kotsopoulos IC; Chandrasekaran D; Gomes N; Butler J; Nobbenhuis M; Ind T; Heath O; Barton D; Jeyarajah A; Brockbank E; Lawrence A; Dilley J; Manchanda R; Phadnis S; Soar GO
Int J Gynecol Cancer; 2022 Dec; 32(12):1606-1610. PubMed ID: 36379595
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
Zhao M; Qiu S; Wu X; Miao P; Jiang Z; Zhu T; Xu X; Zhu Y; Zhang B; Yuan D; Zhang Y; Sun W; He A; Zhao M; Hou W; Zhang Y; Shao Z; Jia M; Li M; Chen J; Xu J; Chen B; Zhou Y; Shen Y
Target Oncol; 2023 Nov; 18(6):869-883. PubMed ID: 37847485
[TBL] [Abstract][Full Text] [Related]
27. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
28. Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
Marth C; Abreu MH; Andersen KK; Aro KM; de Lurdes Batarda M; Boll D; Ekmann-Gade AW; Haltia UM; Hansen J; Haug AJ; Høgdall C; Korach J; Lassus H; Lindemann K; Van Nieuwenhuysen E; Ottevanger PB; Polterauer S; Schnack TH
Cancer; 2022 Aug; 128(16):3080-3089. PubMed ID: 35714310
[TBL] [Abstract][Full Text] [Related]
29. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
[TBL] [Abstract][Full Text] [Related]
30. Health care professionals' attitudes towards population-based genetic testing and risk-stratification for ovarian cancer: a cross-sectional survey.
Hann KEJ; Fraser L; Side L; Gessler S; Waller J; Sanderson SC; Freeman M; Jacobs I; Lanceley A;
BMC Womens Health; 2017 Dec; 17(1):132. PubMed ID: 29246147
[TBL] [Abstract][Full Text] [Related]
31. Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
Gressel GM; Frey MK; Norquist B; Senter L; Blank SV; Urban RR
Gynecol Oncol; 2024 Feb; 181():170-178. PubMed ID: 38215513
[TBL] [Abstract][Full Text] [Related]
32. Refocusing cancer multidisciplinary team meetings in the United Kingdom: comparing urology with other specialties.
Warner R; Hoinville L; Pottle E; Taylor C; Green J
Ann R Coll Surg Engl; 2021 Jan; 103(1):10-17. PubMed ID: 32981347
[TBL] [Abstract][Full Text] [Related]
33. Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
Nag S; Aggarwal S; Rauthan A; Warrier N
J Ovarian Res; 2022 Jul; 15(1):88. PubMed ID: 35902911
[TBL] [Abstract][Full Text] [Related]
34. Educational Value of Surgical Multidisciplinary Team Meetings for Learning Non-Technical Skills - A Pilot Survey of Trainees From Two UK Deaneries.
Trivedi DB
J Surg Educ; 2019; 76(4):1034-1047. PubMed ID: 30792161
[TBL] [Abstract][Full Text] [Related]
35. Management of erectile dysfunction after prostate cancer treatment: cross-sectional surveys of the perceptions and experiences of patients and healthcare professionals in the UK.
Dyer A; Kirby M; White ID; Cooper AM
BMJ Open; 2019 Oct; 9(10):e030856. PubMed ID: 31585974
[TBL] [Abstract][Full Text] [Related]
36. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC; Fleming GF; Lengyel E
Obstet Gynecol; 2021 Jan; 137(1):108-121. PubMed ID: 33278287
[TBL] [Abstract][Full Text] [Related]
37. Peritonectomy and hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer: What gynaecological oncologists really think.
Farrell R
Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):457-462. PubMed ID: 30917208
[TBL] [Abstract][Full Text] [Related]
38. Development of a decision aid for primary treatment of patients with advanced-stage ovarian cancer.
den Ouden JE; The R; Myren BJ; Boll D; Driel WJV; Lalisang RI; Kruitwagen RF; van Altena AM
Int J Gynecol Cancer; 2020 Jun; 30(6):837-844. PubMed ID: 32276940
[TBL] [Abstract][Full Text] [Related]
39. Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Lord R; Rauniyar J; Morris T; Condon O; Jones R; Miller R; Hall M; Lofts F; Glasspool RM; Hudson E
Int J Gynecol Cancer; 2020 Jul; 30(7):1026-1033. PubMed ID: 32321768
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
Giuliani J; Mantoan B; Ferrario L; Candela MV; Aprile G
J Oncol Pharm Pract; 2023 Mar; 29(2):457-464. PubMed ID: 36344039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
